Globe Newswire (Tue, 6-Jan 8:35 AM ET)
The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics
TipRanks (Sun, 4-Jan 8:50 AM ET)
Biggest stock movers Friday: BIDU, RIVN, ASML, and more
Seeking Alpha News (Fri, 2-Jan 10:14 AM ET)
TipRanks (Fri, 2-Jan 9:30 AM ET)
Benzinga (Fri, 2-Jan 8:02 AM ET)
FDA Issues New Setback for Outlook Therapeutics’ LYTENAVA
TipRanks (Fri, 2-Jan 7:58 AM ET)
Biggest stock movers Friday: BIDU, NIO, ASML, and more
Seeking Alpha News (Fri, 2-Jan 6:16 AM ET)
Why is Outlook Therapeutics (OTLK) Stock Down 61% in Pre-Market Trading?
TipRanks (Fri, 2-Jan 6:12 AM ET)
Benzinga (Fri, 2-Jan 5:12 AM ET)
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Benzinga (Fri, 2-Jan 4:30 AM ET)
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics trades on the NASDAQ stock market under the symbol OTLK.
As of January 7, 2026, OTLK stock price climbed to $0.57 with 3,816,680 million shares trading.
OTLK has a beta of 1.47, meaning it tends to be more sensitive to market movements. OTLK has a correlation of 0.02 to the broad based SPY ETF.
OTLK has a market cap of $36.55 million. This is considered a Sub-Micro Cap stock.
Last quarter Outlook Therapeutics reported $-91,787 in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.05.
In the last 3 years, OTLK traded as high as $40.60 and as low as $.50.
The top ETF exchange traded funds that OTLK belongs to (by Net Assets): VTI, VXF, IWC.
OTLK has underperformed the market in the last year with a price return of -75.9% while the SPY ETF gained +17.6%. OTLK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.7% and -69.4%, respectively, while the SPY returned +3.4% and +0.7%, respectively.
OTLK support price is $.49 and resistance is $.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OTLK shares will trade within this expected range on the day.
